Wei Long

SOLID FORMS OF COMPOUND I OR SALTS THEREOF

POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF

1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF

COMPOUNDS TARGETING MUTANT OF P53

N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF

POLYMORPHIC FORMS OF AURORA A SELECTIVE INHIBITORS AND USES THEREOF

Tricyclic Derivatives Useful As PARP7 Inhibitors

Fused Ring Derivatives Useful as KRAS G12D Inhibitors

NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF

NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF

KRAS G12D Inhibitors

KRAS G12D Inhibitors

Novel Glutamine Analogs

Crystalline form of fused pyridine derivative's maleate and uses thereof

Protein tyrosine kinase modulators and methods of use

Polymorphic forms of icotinib phosphate and uses thereof

Protein tyrosine kinase modulators and methods of use

Polymorphic forms of icotinib maleate and uses thereof

Polymorphic forms of icotinib and uses thereof

Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof

Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof

Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

Compound for increasing kinase active and application thereof

Glucagon like peptide analogs, composition, and method of use

Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

Glucagon-like peptide-1 analogues and uses thereof

Compounds as hypoxia mimetics, and compositions and uses thereof

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof